Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...
Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...
Oncology nurses and APPs are key players in patient education on precision medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback